Checkpoint Inhibitor-TKI Combos Effective in RCC
- PMID: 30787015
- DOI: 10.1158/2159-8290.CD-NB2019-024
Checkpoint Inhibitor-TKI Combos Effective in RCC
Abstract
Pembrolizumab or avelumab plus axitinib may be effective first-line treatments for clear-cell advanced renal cell carcinoma. In a pair of phase III trials, the checkpoint inhibitor-tyrosine kinase inhibitor combinations extended progression-free survival compared with sunitinib and were associated with relatively manageable side effects.
©2019 American Association for Cancer Research.
Comment on
-
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16. N Engl J Med. 2019. PMID: 30779529 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical